<DOC>
	<DOCNO>NCT00089427</DOCNO>
	<brief_summary>This Phase 1 study patient newly diagnose malignant glioma design determine high dose IL13-PE38QQR safely administer Convection Enhanced Delivery ( CED ) area around tumor site tumor surgically remove ( resection ) . In addition , patient receive radiation therapy may may treat oral temozolomide .</brief_summary>
	<brief_title>IL13-PE38QQR Infusion After Tumor Resection , Followed Radiation Therapy With Without Temozolomide Patients With Newly Diagnosed Malignant Glioma</brief_title>
	<detailed_description>This Phase I clinical trial experimental drug IL13-PE38QQR ( Study Drug ) patient newly diagnose malignant glioma . IL13-PE38QQR tumor-targeting agent administer continuous infusion directly brain around cavity tumor remove . Through previous research , Study Drug show potential control recurrent malignant glioma , glioblastoma multiforme ( GBM ) , anaplastic astrocytoma , malignant mixed oligoastrocytoma . The Study Drug make combine human protein ( IL13 ) portion bacterial toxin protein , Pseudomonas Exotoxin ( PE ) . The IL13 portion bind receptor tumor like `` key lock , '' allow PE portion enter kill cell . Since tumor cell preferentially bind drug , normal ( healthy ) brain cell much less likely damage drug . The Study Drug deliver tube catheter place directly area surround resection cavity . These catheter surgically place within 14 day tumor remove . A pump use slowly push drug solution catheter use convection-enhanced delivery ( CED ) period 4 day . Following treatment IL13-PE38QQR , patient receive standard course radiation therapy . In addition , patient receive adjuvant temozolomide radiation therapy continue temozolomide radiation therapy complete . Temozolomide anti-cancer drug approve U.S. Food Drug Administration ( FDA ) sell treatment recurrent GBM . This study determine maximum tolerate dose IL13-PE38QQR administer CED tumor resection prior radiation therapy without adjuvant temozolomide . Patients newly diagnose malignant glioma gross total resection tumor meet specify eligibility criterion may enter study . Patients divide 2 group : 1 . Stratum A - receive treatment IL13-PE38QQR follow radiation therapy 2 . Stratum B - receive treatment IL13-PE38QQR follow radiation therapy adjuvant temozolomide . Treatment temozolomide Stratum B continue radiation therapy complete . Subgroups ( cohort ) patient treat 3 dos IL13-PE38QQR . Cohorts 3-6 patient treat dose level . Enrollment subsequent cohort dependent upon safety tolerability treatment previous cohort . All patient need histopathological confirmation malignant glioma diagnosis tissue sample obtain time gross total resection within 14 day stereotactic catheter placement . Each patient 2-4 standard microinfusion catheter place infusion IL13-PE38QQR begin within 24 hour catheter placement . The infusion last 96 hour . Approximately 2 week completion infusion , image radiation therapy planning , physical examination , neurological laboratory assessment perform . Patients , stable , receive standard fractionate external beam radiation therapy total dose 5940-6100 cGy use 180 200 cGy per fraction . For patient assign receive temozolomide combination radiation therapy , dose temozolomide administer day radiation therapy base patient 's body surface area BSA dose 75 mg/m²/day . After radiation therapy complete follow-up MRI reveal stable disease response , patient continue temozolomide use repeat schedule dose 150 -200 mg/m²/day 5 consecutive day per 28 day cycle . Treatment cycle continue 12 cycle .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must ≥18 year old . Patients must undergo gross total resection solid contrastenhancing lesion ( ) &gt; 1.0 cm diameter . Patients must able catheter place within 14 day tumor resection ( include plan Gross Total Resection follow initial biopsy subtotal resection ) Patients must histopathologic confirmation malignant glioma resection specimen . Diagnosis must consistent either GBM , AA , malignant mixed OA . Patients must adequate general condition meet follow criterion : a. Karnofsky Performance Scale score ≥ 70 b . Adequate hematologic status : Absolute neutrophil count ≥ 1,500/mm³ Hemoglobin ≥ 10 gm/dL Platelets ≥ 100,000/mm³ PT &amp; aPTT within institutional limit normal Female patient must pregnant breastfeeding . Patients must practice effective method birth control study 60 day beyond last day infusion . Patients must understand investigational nature study potential risk benefit , sign approve write informed consent prior performance studyspecific procedure . Patients residual contrastenhancing tumor cross midline , multifocal tumor amenable gross total resection nonparenchymal tumor dissemination ( e.g. , subependymal leptomeningeal ) . Patients clinically significant increase ICP ( e.g. , impend herniation ) , uncontrolled seizure requirement immediate palliative treatment . Patients receive prior antitumor treatment ( corticosteroid ) include investigational agent . Patients metallic prosthesis would prevent MRI and/or MRS scanning procedure brain . Patients unwilling unable follow protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>brain tumor</keyword>
	<keyword>malignant glioma</keyword>
	<keyword>brain neoplasm</keyword>
	<keyword>central nervous system</keyword>
	<keyword>surgery</keyword>
	<keyword>resection</keyword>
	<keyword>temozolomide</keyword>
	<keyword>infusion</keyword>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>anaplastic astrocytoma</keyword>
	<keyword>oligoastrocytoma</keyword>
	<keyword>Temodar</keyword>
	<keyword>radiation</keyword>
	<keyword>convection-enhanced delivery</keyword>
	<keyword>GBM</keyword>
</DOC>